Dioseve Inc.

About Dioseve Inc.

Dioseve Inc. aims to provide innovative solutions for infertility by leveraging world-class reproductive cell technology. The company addresses the decline in egg and sperm function due to aging, striving to offer new possibilities for all individuals desiring to have children.

Products & Services

DIOS-001:A product or pipeline focused on reproductive technology (specific details not provided in the content).

Platform Technology:A proprietary differentiation induction technology that efficiently induces oocyte and ovarian somatic cells from iPS cells, aiming to solve previously unaddressed challenges in reproductive health.

Specialties

Reproductive Cell Technology iPS Cell Differentiation Infertility Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 7000000 MR: - FA: 7 million USD FAN: 7000000	D: 2024-06-27 FD: 2024-06-27	7 investors

Equity Latest

2024-06-27

$7.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

岸

岸田和真

Representative Director

清

清田弥寿成

Principal Scientist

貴

貴志かさね

Technical Manager / Senior Scientist

石

石黒光成

Senior Development Manager

椎

椎木義統

Clinical Development Advisor

菅

菅沼信彦

Medical Advisor

View 4 more team members with Pro

Unlock Full Team Directory

Recent News

Dioseve Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised